Works matching IS 19466234 AND DT 2019 AND VI 11 AND IP 491

Results: 7

Discovery of short-course antiwolbachial quinazolines for elimination of filarial worm infections.

Published in:

Science Translational Medicine, 2019, v. 11, n. 491, p. N.PAG, doi. 10.1126/scitranslmed.aav3523

By:

Bakowski, Malina A.;
Shiroodi, Roohollah Kazem;
Liu, Renhe;
Olejniczak, Jason;
Yang, Baiyuan;
Gagaring, Kerstin;
Guo, Hui;
White, Pamela M.;
Chappell, Laura;
Debec, Alain;
Landmann, Frédéric;
Dubben, Bettina;
Lenz, Franziska;
Struever, Dominique;
Ehrens, Alexandra;
Frohberger, Stefan J.;
Sjoberg, Hanna;
Pionnier, Nicolas;
Murphy, Emma;
Archer, John

Publication type:

Article

HBEGF<sup>+</sup> macrophages in rheumatoid arthritis induce fibroblast invasiveness.

Published in:

Science Translational Medicine, 2019, v. 11, n. 491, p. N.PAG, doi. 10.1126/scitranslmed.aau8587

By:

Kuo, David;
Ding, Jennifer;
Cohn, Ian S.;
Zhang, Fan;
Wei, Kevin;
Rao, Deepak A.;
Rozo, Cristina;
Sokhi, Upneet K.;
Shanaj, Sara;
Oliver, David J.;
Echeverria, Adriana P.;
DiCarlo, Edward F.;
Brenner, Michael B.;
Bykerk, Vivian P.;
Goodman, Susan M.;
Raychaudhuri, Soumya;
Rätsch, Gunnar;
Ivashkiv, Lionel B.;
Donlin, Laura T.

Publication type:

Article

Tinkering with the vasopressin pathway in autism.

Published in:

Science Translational Medicine, 2019, v. 11, n. 491, p. N.PAG, doi. 10.1126/scitranslmed.aax7315

By:

Forgeot d'Arc, Baudouin;
Mottron, Laurent;
Elsabbagh, Mayada;
Jacquemont, Sébastien

Publication type:

Article

A randomized placebo-controlled pilot trial shows that intranasal vasopressin improves social deficits in children with autism.

Published in:

Science Translational Medicine, 2019, v. 11, n. 491, p. N.PAG, doi. 10.1126/scitranslmed.aau7356

By:

Parker, Karen J.;
Oztan, Ozge;
Libove, Robin A.;
Mohsin, Noreen;
Karhson, Debra S.;
Sumiyoshi, Raena D.;
Summers, Jacqueline E.;
Hinman, Kyle E.;
Motonaga, Kara S.;
Phillips, Jennifer M.;
Carson, Dean S.;
Fung, Lawrence K.;
Garner, Joseph P.;
Hardan, Antonio Y.

Publication type:

Article

A phase 2 clinical trial of a vasopressin V1a receptor antagonist shows improved adaptive behaviors in men with autism spectrum disorder.

Published in:

Science Translational Medicine, 2019, v. 11, n. 491, p. N.PAG, doi. 10.1126/scitranslmed.aat7838

By:

Bolognani, Federico;
del Valle Rubido, Marta;
Squassante, Lisa;
Wandel, Christoph;
Derks, Michael;
Murtagh, Lorraine;
Sevigny, Jeff;
Khwaja, Omar;
Umbricht, Daniel;
Fontoura, Paulo

Publication type:

Article

Metabolic reprogramming toward oxidative phosphorylation identifies a therapeutic target for mantle cell lymphoma.

Published in:

Science Translational Medicine, 2019, v. 11, n. 491, p. N.PAG, doi. 10.1126/scitranslmed.aau1167

By:

Zhang, Liang;
Yao, Yixin;
Zhang, Shaojun;
Liu, Yang;
Guo, Hui;
Ahmed, Makhdum;
Bell, Taylor;
Zhang, Hui;
Han, Guangchun;
Lorence, Elizabeth;
Badillo, Maria;
Zhou, Shouhao;
Sun, Yuting;
Di Francesco, M. Emilia;
Feng, Ningping;
Haun, Randy;
Lan, Renny;
Mackintosh, Samuel G.;
Mao, Xizeng;
Song, Xingzhi

Publication type:

Article

TGF-β type 2 receptor–mediated modulation of the IL-36 family can be therapeutically targeted in osteoarthritis.

Published in:

Science Translational Medicine, 2019, v. 11, n. 491, p. N.PAG, doi. 10.1126/scitranslmed.aan2585

By:

Li, Tieshi;
Chubinskaya, Susan;
Esposito, Alessandra;
Jin, Xin;
Tagliafierro, Lidia;
Loeser, Richard;
Hakimiyan, Arnavaz A.;
Longobardi, Lara;
Ozkan, Huseyin;
Spagnoli, Anna

Publication type:

Article